: Immune-marker expression of A(H1N1)pdm09-specific CD4 + T-cell responses (Study A). Adults 18-60 years of age received AS03-adjuvanted A(H1N1)pdm09 ('H1N1') vaccine containing 3.75 µg hemagglutinin (HA), or non-adjuvanted H1N1 vaccine containing 15 µg HA, at Day (D) 0 and D21. Data for the per-protocol cohort at Month (M) 12 are reported as percentages of A(H1N1)pdm09-specific CD4 + T cells expressing at least the indicated immune marker and another, among interferon-gamma (IFN-γ), interleukin-2 (IL-2), tumor necrosis factor-alpha (TNF-α), and CD40L per million CD4 + T cells, with medians, first and third quartiles and the minimum/maximum values measured, after stimulation with H1N1 split antigen. Data for D0 and D42 supplements previously published data for the cohort evaluated in terms of CD4 + T cells expressing at least 2 immune markers (1).
